Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,409 clinical trials
J Jenny Chang, MD

Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative surgery will be eligible for participation in the study. The study will …

18 years of age All Phase 1
X Xiangyu Kong, MD

Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer

This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD1/PDL1 therapy in the advanced gastric cancer.

18 years of age All Phase N/A
Y Ying Yang, MD

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

The purpose of this study is to evaluate the efficacy of chemotherapy plus radiotherapy to patients with CA19-9-elevated Advanced Pancreatic Cancer who are not refractory to chemotherapy.

18 - 80 years of age All Phase 3
W Wenjin Yin

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.

18 years of age All Phase 2
C Chang Wang

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

This is a single-center, single-arm study designed to evaluate the efficacy and safety of second-line treatment in patients with advanced colorectal cancer (those who have progressed on or are intolerant to first-line oxaliplatin-based regimens with or without targeted therapy) receiving Levofolinic Acid + 5-FU continuous infusion combined with irinotecan hydrochloride …

18 - 75 years of age All Phase 2
F Florian Huemer, Priv.Doz. Dr

AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall …

18 years of age All Phase N/A
J Jacco J. de Haan, MD, PhD

EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors

To explore the effectiveness of EMDR therapy treatment in reducing symptoms of chemotherapy-induced conditioned nausea and vomiting in (former) patients with cancer.

16 years of age All Phase N/A
S Seock-Ah Im

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD).

19 years of age Female Phase 2
C Cancer Connect

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DESCRIPTION: Prostate cancer (PC) patients receive androgen deprivation therapy (ADT), but recalcitrant disease recurs typically within 2-3 years, referred to as the Castration Resistant Prostate …

18 years of age Male Phase 1
F Fei Ma

Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer

This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced hormone receptor-positive / human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.

18 years of age All Phase N/A

Simplify language using AI